Dendritic Cells Induce Clec5a-mediated Immune Modulation in MPTP-induced Parkinson's Disease Mouse Model

Area of Science:

• Neuroscience
• Immunology

Background:

• Parkinson's disease (PD) involves dopaminergic neuron loss and neuroinflammation.
• Tolerogenic dendritic cells (tolDCs) modulate immune responses but their role in PD is unclear.

Purpose of the Study:

• Investigate the role of C-type lectin domain family 5 member A (Clec5a) in tolDC function.
• Evaluate the therapeutic potential of Clec5a-expressing DCs in a PD mouse model.

Main Methods:

• Analyzed gene expression in tolDCs to identify Clec5a induction.
• Generated Clec5a-knockdown tolDCs to assess cytokine production (IL-10, IL-6) and regulatory T cell (Treg) induction.
• Administered Clec5a-expressing DCs in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mouse model.
• Assessed dopaminergic neuron survival, alpha-synuclein (α-syn) accumulation, neuroinflammation, and behavior.

Main Results:

• Clec5a knockdown reduced tolDC immunomodulatory function, decreased IL-10, increased IL-6, and impaired Treg induction.
• Clec5a-expressing DCs in the PD model reduced dopaminergic neuron loss and α-syn accumulation.
• Treated mice showed reduced brain inflammation and improved locomotor activity.

Conclusions:

• Clec5a is essential for tolDC immunomodulatory activity.
• Clec5a-expressing DCs show therapeutic potential for Parkinson's disease by reducing neuroinflammation and protecting neurons.